ImmunoCellular Therapeutics Valuation
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
ImmunoCellular Therapeutics is overvalued. ImmunoCellular Therapeutics retains a regular Real Value of $0.45 per share. The prevalent price of the firm is $0.47. Our model calculates the value of ImmunoCellular Therapeutics from evaluating the firm fundamentals such as Return On Asset of -4.4, return on equity of -23.12, and Shares Owned By Insiders of 94.96 % as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that ImmunoCellular Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of ImmunoCellular Therapeutics is based on 3 months time horizon. Increasing ImmunoCellular Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ImmunoCellular Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmunoCellular Pink Sheet. However, ImmunoCellular Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.47 | Real 0.45 | Hype 0.47 | Naive 0.45 |
The real value of ImmunoCellular Pink Sheet, also known as its intrinsic value, is the underlying worth of ImmunoCellular Therapeutics Company, which is reflected in its stock price. It is based on ImmunoCellular Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImmunoCellular Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImmunoCellular Therapeutics helps investors to forecast how ImmunoCellular pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmunoCellular Therapeutics more accurately as focusing exclusively on ImmunoCellular Therapeutics' fundamentals will not take into account other important factors: ImmunoCellular Therapeutics Total Value Analysis
ImmunoCellular Therapeutics is currently anticipated to have valuation of (1.69 M) with market capitalization of 2.21 M, debt of 2.78 M, and cash on hands of 933.15 K. The negative valuation of ImmunoCellular Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the ImmunoCellular Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.69 M) | 2.21 M | 2.78 M | 933.15 K |
ImmunoCellular Therapeutics Asset Utilization
One of the ways to look at asset utilization of ImmunoCellular is to check how much profit was generated for every dollar of assets it reports. ImmunoCellular Therapeutics retains a negative application of resources of -4.4 (percent), losing $0.044 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of ImmunoCellular Therapeutics shows how discouraging it operates for each dollar spent on its resources.ImmunoCellular Therapeutics Ownership Allocation
ImmunoCellular Therapeutics retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 94.96 (percent) of ImmunoCellular Therapeutics outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event.ImmunoCellular Therapeutics Profitability Analysis
Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ImmunoCellular Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ImmunoCellular Therapeutics and how it compares across the competition.
About ImmunoCellular Therapeutics Valuation
The pink sheet valuation mechanism determines ImmunoCellular Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of ImmunoCellular Therapeutics. We calculate exposure to ImmunoCellular Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ImmunoCellular Therapeutics's related companies.Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
8 Steps to conduct ImmunoCellular Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates ImmunoCellular Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct ImmunoCellular Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain ImmunoCellular Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine ImmunoCellular Therapeutics' revenue streams: Identify ImmunoCellular Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research ImmunoCellular Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish ImmunoCellular Therapeutics' growth potential: Evaluate ImmunoCellular Therapeutics' management, business model, and growth potential.
- Determine ImmunoCellular Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate ImmunoCellular Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
ImmunoCellular Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -6.6 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |